Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Amaria

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2012
Vemurafenib: the road to personalized medicine in melanomaR N Amaria, K D Lewis, A Jimeno
Drugs of Today (Barcelona, Spain : 1998)|July 31, 2012
Vismodegib in basal cell carcinomaR N Amaria, D W Bowles, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2018
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classificationL Liu, J M Toung, A F Jassowicz, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsV Gopalakrishnan, C N Spencer, L Nezi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2012
Vemurafenib: the road to personalized medicine in melanomaR N Amaria, K D Lewis, A Jimeno
Drugs of Today (Barcelona, Spain : 1998)|July 31, 2012
Vismodegib in basal cell carcinomaR N Amaria, D W Bowles, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2018
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classificationL Liu, J M Toung, A F Jassowicz, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsV Gopalakrishnan, C N Spencer, L Nezi, et al.
Pageof 1